Next Article in Journal
Traumatic Brain Injury, Sleep, and Melatonin—Intrinsic Changes with Therapeutic Potential
Next Article in Special Issue
Relationship between the Biological Clock and Inflammatory Bowel Disease
Previous Article in Journal
Effects on Sleep Quality of Physical Exercise Programs in Older Adults: A Systematic Review and Meta-Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Association of Sleep Reactivity and Anxiety Sensitivity with Insomnia-Related Depression and Anxiety among City Government Employees in Japan

1
Behavioral Sleep Medicine and Sciences Laboratory, Department of Psychological Counseling, Faculty of Humanities, Tokyo Kasei University, Itabashi-ku, Tokyo 173-8602, Japan
2
Department of Psychiatry, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu 520-2192, Japan
*
Author to whom correspondence should be addressed.
Collaborators of the NinJa Sleep Study Group is provided in the Acknowledgments.
Clocks & Sleep 2023, 5(2), 167-176; https://doi.org/10.3390/clockssleep5020015
Submission received: 13 February 2023 / Revised: 12 March 2023 / Accepted: 16 March 2023 / Published: 28 March 2023
(This article belongs to the Special Issue Role of Sleep and Circadian Rhythms in Health III)

Abstract

:
It has recently been noted that a reduction in sleep reactivity, characterized as the trait-like degree to which exposure to stress interferes with sleep, and anxiety sensitivity are associated with reduced insomnia severity. This study aimed to examine whether sleep reactivity and anxiety sensitivity are associated with insomnia-related depression and anxiety among city government employees in Japan. This cross-sectional study included 1810 city government employees of Koka City, Japan (mean age (standard deviation): 45.33 (12.20) years) who completely answered the scales for sleep reactivity, anxiety sensitivity, anxiety, and depression. Stepwise multiple regression analysis adjusted for demographic data showed that anxiety sensitivity (β = 0.39) was significantly linked to anxiety, and sleep reactivity (β = 0.36) was significantly linked to depression in individuals with insomnia. Additionally, the results of a logistic regression analysis adjusted for demographic data showed that anxiety sensitivity and sleep reactivity were relevant factors for anxious insomnia (OR = 12.69) and depressive insomnia (OR = 8.73), respectively. Whereas both sleep reactivity (OR = 14.67) and anxiety sensitivity (OR = 6.14) were associated with combined insomnia. These findings indicate that sleep reactivity is strongly associated with depressive symptoms, and anxiety sensitivity is strongly associated with anxiety symptoms in individuals with insomnia.

1. Introduction

Approximately 20–40% of the general population has been reported to experience insomnia symptoms [1,2,3], and nearly 17% of them experience chronic insomnia [3]. In addition, insomnia can present throughout one’s the lifespan and it can often be chronic [1,2], which is associated with the onset or recurrence of depression and resistance to depression treatment [4,5,6].
During the coronavirus disease 2019 (COVID-19) pandemic, insomnia became a serious issue. In an international collaborative study [7], 36.7% of the community sample complained of insomnia symptoms. Insomnia during the pandemic was associated with symptoms of posttraumatic stress and psychological distress [8]. In addition, infection anxiety during COVID-19 was associated with insomnia, depression, and anxiety [9]. Furthermore, individuals diagnosed with COVID-19 had a higher risk of a subsequent onset of insomnia disorder than those infected with other viruses (e.g., influenza) [10,11].
Cognitive behavioral therapy for insomnia (CBT-I) has been found to be an effective treatment and is recommended as a first-line intervention for chronic insomnia disorder [12,13,14]. A meta-analysis of the mediating factors on improving insomnia symptoms using CBT-I showed that changes in dysfunctional beliefs about sleep and pre-sleep arousal significantly mediated improvement in insomnia symptoms [15]. However, it has recently been noted that reduced sleep reactivity and anxiety sensitivity are associated with increased insomnia severity [16,17].
Sleep reactivity is characterized as the trait-like degree to which exposure to stress interferes with sleep, resulting in difficulty falling and staying asleep [18]. Individuals with a higher sleep reactivity showed a longer sleep latency, greater number of awakenings, and higher somatic arousal [19,20]. Recently, sleep reactivity has become an indicator of vulnerability to the onset of insomnia, with higher sleep reactivity related to an increased risk of depression [21], and insomnia functions as a mediator between sleep reactivity and depression [22]. It is also known that higher sleep reactivity is related to a higher severity of depression and anxiety during insomnia [23].
Anxiety sensitivity is defined as the fear of negative consequences associated with anxiety arousal, and it has been identified as a vulnerability to the onset of panic disorder [24,25]. It was one type of anxiety disorder characterized by repeated and frequently unanticipated panic attacks. Furthermore, anxiety sensitivity is considered a predisposing condition of insomnia [26], which is a mediating factor between sleep anticipatory anxiety and sleep latency [27], and decreases the frequency of sleep-related daytime impairment and using hypnotics [28].
Although there are no studies showing that sleep reactivity and anxiety sensitivity are associated with specific physical diseases, anxiety sensitivity has been found to be associated with pain severity in headaches [29].
It has been reported that these arousal factors are decreased by CBT-I. For example, digital CBT-I for workers with insomnia was more effective in reducing sleep reactivity (Hedges’ g = −1.09) compared to the wait-list control [30]. In addition, cognitive anxiety sensitivity treatment (CAST) targeted towards anxiety sensitivity is effective in improving insomnia via a reduction in anxiety sensitivity [17,31].
Sleep reactivity is likely to be associated with insomnia-related depression, and anxiety sensitivity is associated with insomnia-related anxiety. However, previous studies have examined depression and anxiety symptoms without adequately distinguishing between their symptoms. A systematic review revealed that insomnia predicted the onset of depression (odds ratio [OR] = 2.83) and anxiety (OR = 3.23) [6]. Furthermore, CBT-I is effective in treating insomnia with depression and anxiety comorbidities [32]. Therefore, it is assumed that a reduction in these arousal factors leads to an improvement, and subsequently, a reduction in the symptoms of symptoms depression and anxiety. If this hypothesis is proven, it becomes apparent which characteristics of anxiety sensitivity and sleep reactivity cause specific emotional problems. In particular, a tendency for an increased risk of mortality associated with the use of hypnotics in individuals with insomnia was reported [33]; the development and provision of more effective non-pharmacologic treatment is certainly important.
The present study aimed to examine whether sleep reactivity and anxiety sensitivity are associated with insomnia-related depression and anxiety among city government employees in Japan. We took advantage of this research to study the unique impact of sleep reactivity and anxiety sensitivity on specific emotions.

2. Results

A total 1810 employees (699 males, 1111 females; mean age (standard deviation) 45.33 (12.20) years) completely responded to the measures (Figure 1). In this study, 4.4% were taking sleep medication, 3.3% antianxiety medication, and 2.4% antidepressants. Of them, 0.6% had cardiovascular infarction, 0.9% had cerebral infarction, and 11.7% were shift workers.
The participants were classified into five categories based on the cutoff scores for the Athens Insomnia Scale (AIS), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) are as follows: normal control, insomnia alone, anxious insomnia, depressive insomnia, and combined insomnia. The proportion of normal control was 52.5% and the insomnia category was 11.7%, which included insomnia alone, anxious insomnia, depressive insomnia, and combined insomnia. The proportions of patients with insomnia alone, anxious insomnia, depressive insomnia, and combined insomnia were 4.3%, 3.3%, 10.4%, and 82.0%, respectively. The descriptive statistics of all scales are presented in Table 1.
The exploratory factor analysis (EFA) on all the items of the Ford Insomnia Response to Stress Test (FIRST) and the Anxiety Sensitivity Index (ASI) revealed a two-factor structure; sleep reactivity (all items of the FIRST; factor loadings: 0.30–0.95) and anxiety sensitivity (all items of the ASI; factor loadings: 0.37–0.83). The correlation coefficient (r) between the factors was 0.46 (Table 2).
As the results of a stepwise multiple regression analysis adjusted for the demographic data in individuals with insomnia, for anxiety, that of ASI (β = 0.39, p < 0.001) was significantly linked to GAD-7 (R2 = 0.25 p < 0.001) in Step 1, and both ASI (β = 0.29, p < 0.001) and FIRST (β = 0.24, p < 0.001) were linked to GAD-7 in Step 2 (R2 = 0.30, p < 0.001), but the ΔR2 value was slightly increased (ΔR2 = 0.04; Table 3).
For depression, the FIRST (β = 0.36, p < 0.001) was related to PHQ-9 (R2 = 0.22, p < 0.001) in Step 1, and both the FIRST (β = 0.29, p < 0.001) and ASI (β = 0.16, p < 0.001) were significantly related to the PHQ-9 in Step 2 (R2 = 0.24, p < 0.001), but the ΔR2 value was slightly increased (ΔR2 = 0.02; Table 3).
The results of a logistic regression analysis adjusted for demographic data showed that ASI (OR = 12.69, p < 0.05) was a relevant factor for anxious insomnia, but FIRST (OR = 5.86, p = 0.052) was marginally significant. For depressive insomnia, FIRST (OR = 8.73, p < 0.001) was the only relevant factor, and both FIRST (OR = 14.67, p < 0.001) and ASI (OR = 6.14, p < 0.001) were related to combined insomnia (Table 4).
We conducted a post hoc power analysis using the results of a multiple regression analysis for GAD-7 and PHQ-9 in this study. With a regression dfs of 10, the residual df of 198, the f2 [R2] of 0.43 [0.30] and 0.32 [0.24], and α = 0.001, the power (1 − β) were estimated at 0.99 and 0.99, respectively.

3. Discussion

This study aimed to examine whether sleep reactivity and anxiety sensitivity are associated with insomnia-related depression and anxiety among city government employees in Japan. The results showed that sleep reactivity was strongly associated with depressive symptoms such as hopeless, little energy, and poor appetite, and anxiety sensitivity was highly associated with anxiety symptoms such as nervousness, worry, and irritability.
In this study, pathological insomnia was defined as an AIS ≥ 10 points, and the proportion was approximately 12%. The prevalence of insomnia with daytime impairment has been reported to be approximately 17% [3]; the proportion of the individuals classified as insomniacs in this study is similar to that of the clinical level of insomnia.
The results of the EFA showed that sleep reactivity determined by FIRST and anxiety sensitivity identified by ASI were different constructs. This is remarkable because both sleep reactivity and anxiety sensitivity are regarded as predisposing factors for physiological arousal from insomnia.
The results of multiple regression analysis revealed that both sleep reactivity and anxiety sensitivity were associated with depression and anxiety symptoms in individuals with clinical level of insomnia. Considering the small ΔR2 value, sleep reactivity is particularly associated with depression, and anxiety sensitivity is related to anxiety. These findings are in line with those of previous studies [22,27]. Sleep reactivity directly and indirectly affects the onset of depression via the onset of insomnia [22], and anxiety sensitivity is a mediating factor between sleep anticipatory anxiety and sleep latency [27]. Similarly, the results of logistic regression analysis revealed that sleep reactivity was related to insomnia-related depression, while anxiety sensitivity was only associated with insomnia-related anxiety.
It is suggested that high levels of sleep reactivity and anxiety sensitivity might increase negative emotions in individuals with insomnia. Sleep reactivity is involved in a wide range of emotional responses in insomnia since sleep reactivity was also marginally associated with anxious insomnia. It is remarkable for predicting and preventing the subsequent onset of depression and anxiety disorders due to insomnia. CBT-I is an effective treatment for reducing insomnia severity and the mental symptoms of insomniacs with comorbid depression and anxiety disorders [34]. For example, the remission rates of CBT-I with eight weekly sessions were reported to be 57% at post-treatment and 56% at the 6-month follow-up [35]. In addition, reductions in sleep reactivity and anxiety sensitivity by CBT-I are likely to be significant mediators that reduce the severity of insomnia [16,17]. Thus, reducing both mediators as predisposing factors may prevent the recurrence of insomnia and improve insomnia-derived anxiety and depressive disorders.
Currently, a CAST with a single session has been developed as an approach to directly reduce anxiety sensitivity and improve insomnia symptoms by reducing anxiety sensitivity [31]; however, no direct approach for sleep reactivity has been developed. It is suggested that low/high sleep reactivity may be involved in the treatment response to CBT-I [16,18], although the reason for the reduction in sleep reactivity by CBT-I is not clear. In the future, an approach for the direct reduction in sleep reactivity should be developed and the mechanism of action should be examined.
This present study has some limitations. First, although this was a cross-sectional study, we were unable to identify causal relationships among sleep reactivity, anxiety sensitivity, insomnia, depression, and anxiety. Future prospective and longitudinal studies are needed to evaluate the influence of sleep reactivity and anxiety sensitivity on changes in insomnia-related depression and anxiety. Second, the participants were classified into insomnia categories using the cut-off scores for AIS, GAD-7, and PHQ-9, but not using the diagnostic criteria for these disorders. Therefore, additional studies are needed for patients with insomnia who have comorbid anxiety and/or depressive disorders. Third, participants in this study were limited to city government employees. It is necessary to confirm whether similar results can be obtained in a community sample in the future. Finally, we did not measure objective sleep parameters, such as electroencephalography. Depressive symptoms are associated with prolonged objective sleep and reduced rapid eye movement latency [36]. It is necessary to examine the relationship between sleep reactivity, anxiety sensitivity and the sleep architecture of depressive and anxious insomnia in the future.

4. Materials and Methods

4.1. Participants

A total of 2081 participants were government employees at Koka City, which is a rural city in Shiga Prefecture, Japan. The employees for whom the consent of a legal representative was required for participation were excluded from this study. Questionnaires were distributed to these employees, and a total of 1852 participants returned the questionnaire. Of these, 1810 employees completely responded to the measures (Figure 1). The questionnaire survey was conducted from 1 October 2021 to 18 March 2022.

4.2. Measures

4.2.1. Demographic Data

We collected age, sex, a kind medication taken (hypnotics, antianxiety medication, and antidepressants), the presence of cardiovascular and neurological diseases, and shift-worker status as demographic data.

Insomnia-Related Measures

The Japanese version of the AIS was used to measure insomnia severity [37,38,39]. The scale consists of eight items, and the total score was calculated, with lower scores indicating a lower insomnia severity. The severity level of insomnia has been categorized as subthreshold (0–5 points), mild (6–9 points), moderate (10–15 points), and severe (≥16 points) [39]. When individuals received the AIS scores of ≥10 points, they were expected to be diagnosed with insomnia in the cohort study [5]; therefore, individuals with AIS scores of ≥10 points were considered to have psychopathological insomnia in the study.
The Japanese version of the FIRST was used to measure sleep reactivity [19,40]. The scale consists of 9 items, and the total score was calculated, with lower scores indicating less sleep reactivity to stress.
The Japanese version of the ASI was used to measure anxiety sensitivity [24,41]. The scale consists of 16 items, and the total score was calculated, with lower scores indicating less anxiety sensitivity.

4.2.2. Anxiety and Depression

The Japanese versions of the GAD-7 [42,43] and PHQ-9 [44,45] were used to measure symptoms of anxiety and depression, respectively. The GAD-7 consists of seven items, the PHQ-9 consists of nine items, and both scales have been recommended to assess symptoms of anxiety and depression, as listed in the DSM-5 [46]. The total scores for both scales were calculated, with higher scores indicating more anxiety or depression. Cutoff scores of 5 were determined for both scales [42,44]; therefore, individuals with the GAD-7 or PHQ-9 scores of ≥5 points were considered to have psychopathological anxiety or depression in this study.

4.3. Procedure

A cross-sectional study was performed as part of the Night in Japan Home Sleep Monitoring (NinJaSleep) Study, which is an epidemiological study on sleep and mental health [36]. The study was approved by the ethics committee of Shiga University of Medical Science (R2017-111), and written informed consent was obtained from each participant.

4.4. Sample Size

The sample size was calculated based on a power analysis using an effect size f2, which was calculated with multiple regression analysis. With f2 = 0.15 (moderate effect size), α = 0.01, power (1 − β) estimated at 0.80, it was calculated that the total sample size was 160. Since, in the general population, it has been reported that nearly 17% of them experience chronic insomnia [3], we recruited a thousand participants or more.

4.5. Statistical Analysis

An exploratory factor analysis (EFA) using the maximum likelihood method with promax rotation was conducted to ensure that the FIRST and ASI are different constructs because the FIRST was associated with trait anxiety [40]. Then, to examine whether sleep reactivity and anxiety sensitivity are associated with anxiety or depressive symptoms in individuals with insomnia, we performed a stepwise multiple regression analysis adjusted for demographic data with the FIRST and ASI as independent variables and the GAD-7 or PHQ-9 as dependent variables. An effect size for R2 value of >0.02 indicates a small effect, >0.13 indicates a moderate effect, and >0.26 indicates a large effect [47]. In addition, the ΔR2 value of >0.07 indicates a medium effect size [48].
The participants were classified into five categories based on the cutoff scores for AIS, GAD-7, and PHQ-9, which are as follows: normal control (AIS ≤ 9, GAD-7 ≤ 4, and PHQ-9 ≤ 4), insomnia alone (AIS ≥ 10, GAD-7 ≤ 4, and PHQ-9 ≤ 4), anxious insomnia (AIS ≥ 10, GAD-7 ≥ 5, and PHQ-9 ≤ 4), depressive insomnia (AIS ≥ 10, GAD-7 ≤ 4, and PHQ-9 ≥ 5), and combined insomnia (AIS ≥ 10, GAD-7 ≥ 5, and PHQ-9 ≥ 5). In addition, sleep reactivity and anxiety sensitivity were divided into high and low groups based on the mean scores for the FIRST and ASI, respectively. Using these classifications, we performed a logistic regression analysis with normal control versus anxious insomnia, normal control versus depressive insomnia, and normal control versus combined insomnia as dependent variables, and high/low sleep reactivity and anxiety sensitivity as independent variables, adjusted for demographic data.
The data were analyzed using SPSS Version 26.0 (IBM Inc., Tokyo, Japan).

5. Conclusions

Sleep reactivity was strongly related to depressive symptoms, and anxiety sensitivity was highly associated with anxiety symptoms in city government employees with insomnia in Japan. The findings have important implications for preventing the onset and recurrence of anxiety disorders and depression with insomnia.

Author Contributions

Conceptualization, H.K. and I.O.; methodology, I.O.; formal analysis, I.O.; investigation, the NinJa Sleep Study Group; writing—original draft preparation, I.O.; writing—review and editing, H.K.; project administration, H.K. and I.O.; funding acquisition, H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded in part by the Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC/MSD K.K. to H.K. The opinions expressed in this manuscript are those of the authors and do not necessarily represent those of Merck Sharp & Dohme LLC/MSD K.K.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the ethics committee of Shiga University of Medical Science (R2017-111).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We express our gratitude to the participants of Koka City. We thank T. Toyoda, R. Matsumoto, A. Toguchi, S. Sawada, H. Nakayama, M. Kawasaki, K. Konishi, K. Awazu, and A. Sagara for their assistance with the data collection. The complete list of collaborators in the NinJa Sleep Study is as follows: Hiroshi Kadotani, Chie Omichi, Yukiyoshi Sumi, Ayaka Ubara, Kohei Nishikawa, Arichika Matsuda, Aiko Sagara, Taeko Toyoda, Yuji Ozeki (Department of Psychiatry, Shiga University of Medical Science), Hitoshi Yamanaka, Keitaro Miyaji, and Isao Kikuchi (Koka City).

Conflicts of Interest

I.O. received grants from NEC Solution Innovators Co., Ltd. and Infocom Co.; lecture fees from Otsuka Pharmaceutical Co., Ltd., MSD LLC, and Eisai Co., Ltd., and consultation fees from NEC Solution Innovators Co., Ltd. and Suntory Wellness Ltd. for projects unrelated to the submitted work. H.K. received grants from Eisai Co., Ltd. and the SECOM Science and Technology Foundation. H.K. reports consulting fees from Takeda Pharmaceutical Co., Ltd. H.K., A.U., and A.M. were associated with a laboratory that was supported by donations from Fukuda Lifetech Co., Ltd. and Fukuda Life Tech Keiji Co., Ltd. to Shiga University of Medical Science. The other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Chaput, J.-P.; Yau, J.; Rao, D.P.; Morin, C.M. Prevalence of insomnia for Canadians aged 6 to 79. Public Health Rep. 2018, 29, 16–20. [Google Scholar]
  2. Ito, K.; Kadotani, H.; Okajima, I.; Ubara, A.; Ichikawa, M.; Omichi, C.; Miyamoto, T.; Matsuda, A.; Sumi, Y.; Kitagawa, H. Large Questionnaire Survey on Sleep Duration and Insomnia Using the TV Hybridcast System by Japan Broadcasting Corporation (NHK). Int. J. Environ. Res. Public Health 2021, 18, 2691. [Google Scholar] [CrossRef] [PubMed]
  3. Morin, C.M.; Jarrin, D.C.; Ivers, H.; Mérette, C.; LeBlanc, M.; Savard, J. Incidence, Persistence, and Remission Rates of Insomnia Over 5 Years. JAMA Netw. Open 2020, 3, e2018782. [Google Scholar] [CrossRef] [PubMed]
  4. Okajima, I.; Komada, Y.; Nomura, T.; Nakashima, K.; Inoue, Y. Insomnia as a Risk for Depression: A longitudinal epidemiologic study on a Japanese rural cohort. J. Clin. Psychiatry 2011, 73, 377–383. [Google Scholar] [CrossRef]
  5. Takami, M.; the NinJaSleep Study Group; Kadotani, H.; Nishikawa, K.; Sumi, Y.; Nakabayashi, T.; Fujii, Y.; Matsuo, M.; Yamada, N. Quality of life, depression, and productivity of city government employees in Japan: A comparison study using the Athens insomnia scale and insomnia severity index. Sleep Sci. Pract. 2018, 2, 4. [Google Scholar] [CrossRef]
  6. Hertenstein, E.; Feige, B.; Gmeiner, T.; Kienzler, C.; Spiegelhalder, K.; Johann, A.; Jansson-Fröjmark, M.; Palagini, L.; Rücker, G.; Riemann, D.; et al. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. Sleep Med. Rev. 2019, 43, 96–105. [Google Scholar] [CrossRef]
  7. Morin, C.M.; Bjorvatn, B.; Chung, F.; Holzinger, B.; Partinen, M.; Penzel, T.; Ivers, H.; Wing, Y.K.; Chan, N.Y.; Merikanto, I.; et al. Insomnia, anxiety, and depression during the COVID-19 pandemic: An international collaborative study. Sleep Med. 2021, 87, 38–45. [Google Scholar] [CrossRef]
  8. Fila-Witecka, K.; Malecka, M.; Senczyszyn, A.; Wieczorek, T.; Wieckiewicz, M.; Szczesniak, D.; Piotrowski, P.; Rymaszewska, J. Sleepless in Solitude—Insomnia Symptoms Severity and Psychopathological Symptoms among University Students during the COVID-19 Pandemic in Poland. Int. J. Environ. Res. Public Health 2022, 19, 2551. [Google Scholar] [CrossRef]
  9. Okajima, I.; Chung, S.; Suh, S. Validation of the Japanese version of Stress and Anxiety to Viral Epidemics-9 (SAVE-9) and relationship among stress, insomnia, anxiety, and depression in healthcare workers exposed to coronavirus disease 2019. Sleep Med. 2021, 84, 397–402. [Google Scholar] [CrossRef]
  10. Taquet, M.; Luciano, S.; Geddes, J.R.; Harrison, P.J. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 2021, 8, 130–140. [Google Scholar] [CrossRef]
  11. Taquet, M.; Geddes, J.R.; Husain, M.; Luciano, S.; Harrison, P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry 2021, 8, 416–427. [Google Scholar] [CrossRef]
  12. Qaseem, A.; Kansagara, D.; Forciea, M.A.; Cooke, M.; Denberg, T.D.; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline from the American College of Physicians. Ann. Intern. Med. 2016, 165, 125–133. [Google Scholar] [CrossRef] [Green Version]
  13. Riemann, D.; Baglioni, C.; Bassetti, C.; Bjorvatn, B.; Groselj, L.D.; Ellis, J.G.; Espie, C.A.; Garcia-Borreguero, D.; Gjerstad, M.; Gonçalves, M.; et al. European guideline for the diagnosis and treatment of insomnia. J. Sleep Res. 2017, 26, 675–700. [Google Scholar] [CrossRef] [PubMed]
  14. Edinger, J.D.; Arnedt, J.T.; Bertisch, S.M.; Carney, C.E.; Harrington, J.J.; Lichstein, K.L.; Sateia, M.J.; Troxel, W.M.; Zhou, E.S.; Kazmi, U.; et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine clinical practice guideline. J. Clin. Sleep Med. 2021, 17, 255–262. [Google Scholar] [CrossRef] [PubMed]
  15. Parsons, C.E.; Zachariae, R.; Landberger, C.; Young, K.S. How does cognitive behavioural therapy for insomnia work? A systematic review and meta-analysis of mediators of change. Clin. Psychol. Rev. 2021, 86, 102027. [Google Scholar] [CrossRef] [PubMed]
  16. Ubara, A.; Tanizawa, N.; Harata, M.; Suh, S.; Yang, C.-M.; Li, X.; Okajima, I. How Does E-mail-Delivered Cognitive Behavioral Therapy Work for Young Adults (18–28 Years) with Insomnia? Mediators of Changes in Insomnia, Depression, Anxiety, and Stress. Int. J. Environ. Res. Public Health 2022, 19, 4423. [Google Scholar] [CrossRef]
  17. Short, N.A.; Allan, N.P.; Raines, A.M.; Schmidt, N.B. The effects of an anxiety sensitivity intervention on insomnia symptoms. Sleep Med. 2015, 16, 152–159. [Google Scholar] [CrossRef]
  18. Kalmbach, D.A.; Anderson, J.R.; Drake, C.L. The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. J. Sleep Res. 2018, 27, e12710. [Google Scholar] [CrossRef] [Green Version]
  19. Drake, C.; Richardson, G.; Roehrs, T.; Scofield, H.; Roth, T. Vulnerability to Stress-related Sleep Disturbance and Hyperarousal. Sleep 2004, 27, 285–291. [Google Scholar] [CrossRef]
  20. Chen, I.; Jarrin, D.; Rochefort, A.; Lamy, M.; Ivers, H.; Morin, C. Validation of the French version of the Ford insomnia response to stress test and the association between sleep reactivity and hyperarousal. Sleep Med. 2015, 16, S238. [Google Scholar] [CrossRef]
  21. Nakajima, S.; Komada, Y.; Sasai-Sakuma, T.; Okajima, I.; Harada, Y.; Watanabe, K.; Inoue, Y. Higher sleep reactivity and insomnia mutually aggravate depressive symptoms: A cross-sectional epidemiological study in Japan. Sleep Med. 2017, 33, 130–133. [Google Scholar] [CrossRef] [PubMed]
  22. Drake, C.L.; Pillai, V.; Roth, T. Stress and Sleep Reactivity: A Prospective Investigation of the Stress-Diathesis Model of Insomnia. Sleep 2014, 37, 1295–1304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Kalmbach, D.A.; Pillai, V.; Arnedt, J.T.; Anderson, J.R.; Drake, C.L. Sleep system sensitization: Evidence for changing roles of etiological factors in insomnia. Sleep Med. 2016, 21, 63–69. [Google Scholar] [CrossRef] [Green Version]
  24. Reiss, S.; Peterson, R.A.; Gursky, D.M.; McNally, R.J. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav. Res. Ther. 1986, 24, 1–8. [Google Scholar] [CrossRef] [PubMed]
  25. López, J.O.; González, J.R.B.; García-Palacios, A. Influence of vulnerability factors in panic disorder severity. Psicothema 2016, 28, 167–173. [Google Scholar] [CrossRef] [Green Version]
  26. Spielman, A.J. Assessment of insomnia. Clin. Psychol. Rev. 1986, 6, 11–25. [Google Scholar] [CrossRef]
  27. Babson, K.A.; Trainor, C.D.; Bunaciu, L.; Feldner, M.T. An Examination of Anxiety Sensitivity as a Moderator of the Relation Between Sleep Anticipatory Anxiety and Sleep Onset Latency. J. Cogn. Psychother. 2008, 22, 258–270. [Google Scholar] [CrossRef]
  28. Vincent, N.; Walker, J. Anxiety sensitivity: Predictor of sleep-related impairment and medication use in chronic insomnia. Depress. Anxiety 2001, 14, 238–243. [Google Scholar] [CrossRef]
  29. Farris, S.G.; Burr, E.K.; Abrantes, A.M.; Thomas, J.G.; Godley, F.A.; Roth, J.L.; Lipton, R.B.; Pavlovic, J.M.; Bond, D.S. Anxiety Sensitivity as a Risk Indicator for Anxiety, Depression, and Headache Severity in Women With Migraine. Headache 2019, 59, 1212–1220. [Google Scholar] [CrossRef]
  30. Okajima, I.; Akitomi, J.; Kajiyama, I.; Ishii, M.; Murakami, H.; Yamaguchi, M. Effects of a Tailored Brief Behavioral Therapy Application on Insomnia Severity and Social Disabilities Among Workers With Insomnia in Japan: A randomized clinical trial. JAMA Netw. Open 2020, 3, e202775. [Google Scholar] [CrossRef] [Green Version]
  31. Short, N.A.; Boffa, J.W.; King, S.; Albanese, B.J.; Allan, N.P.; Schmidt, N.B. A randomized clinical trial examining the effects of an anxiety sensitivity intervention on insomnia symptoms: Replication and extension. Behav. Res. Ther. 2017, 99, 108–116. [Google Scholar] [CrossRef] [PubMed]
  32. Ye, Y.-Y.; Zhang, Y.-F.; Chen, J.; Liu, J.; Li, X.-J.; Liu, Y.-Z.; Lang, Y.; Lin, L.; Yang, X.-J.; Jiang, X.-J. Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-i) Improves Comorbid Anxiety and Depression—A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2015, 10, e0142258. [Google Scholar] [CrossRef]
  33. Lovato, N.; Lack, L. Insomnia and mortality: A meta-analysis. Sleep Med. Rev. 2019, 43, 71–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Okajima, I.; Inoue, Y. Efficacy of cognitive behavioral therapy for comorbid insomnia: A meta-analysis. Sleep Biol. Rhythm. 2018, 16, 21–35. [Google Scholar] [CrossRef]
  35. Harvey, A.G.; Bélanger, L.; Talbot, L.; Eidelman, P.; Beaulieu-Bonneau, S.; Fortier-Brochu, E.; Ivers, H.; Lamy, M.; Hein, K.; Soehner, A.M.; et al. Comparative efficacy of behavior therapy, cognitive therapy, and cognitive behavior therapy for chronic insomnia: A randomized controlled trial. J. Consult. Clin. Psychol. 2014, 82, 670–683. [Google Scholar] [CrossRef] [Green Version]
  36. Omichi, C.; Kadotani, H.; Sumi, Y.; Ubara, A.; Nishikawa, K.; Matsuda, A.; Ozeki, Y.; the NinJaSleep Study Group. Prolonged Sleep Latency and Reduced REM Latency Are Associated with Depressive Symptoms in a Japanese Working Population. Int. J. Environ. Res. Public Health 2022, 19, 2112. [Google Scholar] [CrossRef] [PubMed]
  37. Soldatos, C.R.; Dikeos, D.G.; Paparrigopoulos, T.J. The diagnostic validity of the Athens Insomnia Scale. J. Psychosom. Res. 2003, 55, 263–267. [Google Scholar] [CrossRef]
  38. Okajima, I.; Nakajima, S.; Kobayashi, M.; Inoue, Y. Development and validation of the Japanese version of the Athens Insomnia Scale. Psychiatry Clin. Neurosci. 2013, 67, 420–425. [Google Scholar] [CrossRef]
  39. Okajima, I.; Miyamoto, T.; Ubara, A.; Omichi, C.; Matsuda, A.; Sumi, Y.; Matsuo, M.; Ito, K.; Kadotani, H. Evaluation of Severity Levels of the Athens Insomnia Scale Based on the Criterion of Insomnia Severity Index. Int. J. Environ. Res. Public Health 2020, 17, 8789. [Google Scholar] [CrossRef]
  40. Nakajima, S.; Okajima, I.; Sasai, T.; Kobayashi, M.; Furudate, N.; Drake, C.; Roth, T.; Inoue, Y. Validation of the Japanese version of the Ford Insomnia Response to Stress Test and the association of sleep reactivity with trait anxiety and insomnia. Sleep Med. 2014, 15, 196–202. [Google Scholar] [CrossRef]
  41. Matsuoka, H.; Sakano, Y. An examination of factor structure of the Anxiety Sensitivity Index. J. Cent. Clin. Dev. Psychol. 2004, 1, 1–9. (In Japanese) [Google Scholar]
  42. Spitzer, R.L.; Kroenke, K.; Williams, J.B.W.; Löwe, B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Muramatsu, K. Validation of Japanese version of GAD-7. Jpn. J. Psychosom. Med. 2010, 50, 166. (In Japanese) [Google Scholar]
  44. Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2011, 16, 606–613. [Google Scholar] [CrossRef] [PubMed]
  45. Muramatsu, K.; Kamijima, K.; Yoshida, M.; Otsubo, T.; Miyaoka, H.; Muramatsu, Y.; Gejyo, F. The Patient Health Questionnaire, Japanese Version: Validity According to the Mini-International Neuropsychiatric Interview–Plus. Psychol. Rep. 2007, 101, 952–960. [Google Scholar] [CrossRef]
  46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing Inc.: Arlington, VA, USA, 2013. [Google Scholar]
  47. Cohen, J. Statistical Power Analysis for the Behavioral Science, 2nd ed.; Lawrence Erlbaum Associates: Hillsdale, NJ, USA, 1988. [Google Scholar]
  48. Green, S.B. How Many Subjects does It Take to Do A Regression Analysis. Multivar. Behav. Res. 1991, 26, 499–510. [Google Scholar] [CrossRef]
Figure 1. Study flowchart.
Figure 1. Study flowchart.
Clockssleep 05 00015 g001
Table 1. Descriptive statistics (means and SD) for all scales.
Table 1. Descriptive statistics (means and SD) for all scales.
ScalesTotalNormalInsomnia
Alone
Anxious
Insomnia
Depressive
Insomnia
Combined
Insomnia
Sleep reactivity (FIRST)20.55 (6.45)17.90 (5.78)20.89 (4.91)22.00 (7.07)22.68 (7.15)26.87 (4.83)
Anxiety sensitivity (ASI)18.12 (12.13)13.83 (10.74)25.33 (12.48)20.86 (10.96)18.68 (8.89)29.73 (12.85)
Insomnia (AIS)5.14 (3.73)2.99 (2.16)10.56 (0.53)11.00 (1.41)11.36 (1.71)12.81 (2.55)
Anxiety (GAD-7)3.84 (4.20)1.15 (1.24)1.44 (1.33)5.57 (1.13)2.55 (1.22)10.98 (4.20)
Depression (PHQ-9)4.87 (4.73)1.57 (1.36)2.67 (1.58)3.86 (0.38)8.68 (3.17)13.37 (4.64)
AIS, Athens Insomnia Scale; ASI, Anxiety Sensitivity Index; FIRST, Ford Insomnia Response to Stress Test; GAD-7 Generalized Anxiety Scale-7; PHQ-9, Patient Health Questionnaire-9; SD, standard deviation.
Table 2. Results of exploratory factor analysis.
Table 2. Results of exploratory factor analysis.
Factor Loadings
ItemsFactor 1Factor 2
Factor 1: Anxiety sensitivity
ASI 100.83−0.05
ASI 160.810.00
ASI 120.80−0.01
ASI 140.770.04
ASI 150.770.02
ASI 90.77−0.06
ASI 60.760.06
ASI 80.740.04
ASI 40.720.04
ASI 30.710.00
ASI 110.71−0.03
ASI 130.67−0.09
ASI 20.530.05
ASI 50.420.15
ASI 70.410.15
ASI 10.370.10
Factor 2: Sleep reactivity
FIRST 3−0.070.95
FIRST 2−0.040.93
FIRST 4−0.010.86
FIRST 6−0.010.86
FIRST 70.020.78
FIRST 10.030.70
FIRST 80.090.61
FIRST 50.120.43
FIRST 90.150.30
Factor correlation
Factor 10.46
ASI, Anxiety Sensitivity Index; FIRST, Ford Insomnia Response to Stress Test.
Table 3. Multiple regression analysis of factors associated with anxiety and depression in individuals with insomnia.
Table 3. Multiple regression analysis of factors associated with anxiety and depression in individuals with insomnia.
Anxiety (GAD-7)Depression (PHQ-9)
Step 1
Sleep reactivity (FIRST)0.36 **
Anxiety sensitivity (ASI)0.39 **
R20.250.22
Step 2
Sleep reactivity (FIRST)0.24 **0.29 **
Anxiety sensitivity (ASI)0.29 **0.16 **
R2 (ΔR2)0.30 (0.04)0.24 (0.02)
ASI, Anxiety Sensitivity Index; FIRST, Ford Insomnia Response to Stress Test; GAD-7, Generalized Anxiety Scale-7; PHQ-9, Patient Health Questionnaire-9. Adjusted for demographic data. ** p < 0.001.
Table 4. Logistic regression analyses of factors associated with insomnia subtypes.
Table 4. Logistic regression analyses of factors associated with insomnia subtypes.
VariablesAnxious Insomnia
OR [95% CI]
Depressive Insomnia
OR [95% CI]
Combined Insomnia
OR [95% CI]
Sleep reactivity (FIRST)5.86
[0.97, 35.33]
8.73 **
[2.68, 28.40]
14.67 **
[8.30, 25.93]
Anxiety sensitivity (ASI)12.69 *
[1.34, 120.48]
1.83
[0.71, 4.75]
6.14 **
[3.79, 9.95]
ASI, Anxiety Sensitivity Index; FIRST, Ford Insomnia Response to Stress Test; OR, odds ratio; CI, confidence interval. Adjusted for demographic data. * p < 0.05, ** p < 0.001.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Okajima, I.; Kadotani, H.; on behalf of the NinJa Sleep Study Group. Association of Sleep Reactivity and Anxiety Sensitivity with Insomnia-Related Depression and Anxiety among City Government Employees in Japan. Clocks & Sleep 2023, 5, 167-176. https://doi.org/10.3390/clockssleep5020015

AMA Style

Okajima I, Kadotani H, on behalf of the NinJa Sleep Study Group. Association of Sleep Reactivity and Anxiety Sensitivity with Insomnia-Related Depression and Anxiety among City Government Employees in Japan. Clocks & Sleep. 2023; 5(2):167-176. https://doi.org/10.3390/clockssleep5020015

Chicago/Turabian Style

Okajima, Isa, Hiroshi Kadotani, and on behalf of the NinJa Sleep Study Group. 2023. "Association of Sleep Reactivity and Anxiety Sensitivity with Insomnia-Related Depression and Anxiety among City Government Employees in Japan" Clocks & Sleep 5, no. 2: 167-176. https://doi.org/10.3390/clockssleep5020015

Article Metrics

Back to TopTop